RNA Interference News and Research

RSS

Third Annual Cape Cod Walk 'n' Roll for FSH Muscular Dystrophy on October 1

Tomorrow, October 1, 2011, FSHD patients and their friends, advocates, and families will join in the Third Annual Cape Cod Walk 'n' Roll for FSHD.

1 Oct 2011

NIH honors Utah biochemist with Pioneer Award for dsRNA research

University of Utah biochemist Brenda L. Bass, Ph.D., has dedicated her career to following the path less traveled.

23 Sep 2011

Silence receives U.S. patent entitled, 'Use of Protein Kinase N beta'

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces the issuance of patent 4810095 entitled "Use of Protein Kinase N beta" by the Japanese Patent Office.

16 Sep 2011

Polyplus-transfection appoints ten additional biologists and chemists to support multiple pre-clinical studies

Polyplus-transfection SA, which specializes in the development of innovative solutions for the delivery of nucleic acids in research and therapeutics, today celebrates ten years of continuous growth.

15 Sep 2011

InteRNA, Silence partner to develop novel microRNA therapeutics for cancer

Silence Therapeutics plc, a leading global RNA interference (RNAi) therapeutics company, and InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA-based therapeutics for cancer, today announce that they have entered into an agreement to develop novel microRNA therapeutics for the treatment of cancer.

12 Sep 2011

New treatment strategy for dominant forms of muscular dystrophy

Investigators at The Research Institute at Nationwide Children's Hospital are studying a potential new treatment strategy for dominant forms of muscular dystrophy, thanks to preliminary funding from The Ohio State University Center for Clinical and Translational Science.

12 Sep 2011

AMT total net loss decreases 7% to € 8.7 million for first half year of 2011

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2011.

25 Aug 2011

IARS launches $750,000 anesthesia research grant

The International Anesthesia Research Society (IARS) launched a $750,000 research grant today - the largest single grant offered by the Society in its 90 year history. The Frontiers in Anesthesia Research Award, created in 1995, has traditionally been a $500,000 grant.

24 Aug 2011

La Jolla Institute's new RNAi Center to focus on genetics behind myriad diseases

A major Center that will propel scientific efforts to pinpoint the specific genes involved in causing immune diseases, cancer and other diseases will be opened today at the La Jolla Institute for Allergy & Immunology.

12 Aug 2011

New model for amyotrophic lateral sclerosis

By isolating cells from patients' spinal tissue within a few days after death, researchers funded by the National Institutes of Health have developed a new model of the paralyzing disease amyotrophic lateral sclerosis.

12 Aug 2011

World RNA Interference market will be worth $4 billion by 2017: New report

By 2017, the world RNA Interference market will be worth $4 billion, according to a new report available from companiesandmarkets.com.

5 Aug 2011

Myb protein suppression can help eliminate acute myelogenous leukemia

A team of scientists at Cold Spring Harbor Laboratory (CSHL) has laid bare the mechanism behind a phenomenon called oncogene addiction in mice suffering from a form of leukemia that mimics acute myelogenous leukemia (AML) in humans.

1 Aug 2011

Human kinome RNAi screening performed using Roche’s xCELLigence MP Instrument

RNA interference studies are a powerful technology for high-throughput screening. However, endpoint analyses only provide a snapshot of the analyzed cellular phenotype, as it is not possible to measure developmental changes over time.

29 Jul 2011

New transgenic mouse could predict toxicity of targeted cancer drugs

Only one in twenty cancer drugs makes its way from the laboratory to become an approved pharmaceutical product. The majority of new agents are only shown to be unsuitable in the later phases of clinical development which would explain the exorbitantly high development costs of 500 to 600 million euros per new cancer drug.

20 Jul 2011

Researchers identify potential therapeutic target for ER-negative breast cancer

Using a new in vivo screening system, Whitehead Institute researchers have identified a protein in the serine biosynthesis pathway that is essential in estrogen receptor (ER)-negative breast cancer—a notoriously difficult disease to treat associated with low five-year survival rates.

19 Jul 2011

TGen presents two key studies at 14th World Conference on Lung Cancer

The Translational Genomics Research Institute (TGen) is presenting two key studies, including one today, at the 14th World Conference on Lung Cancer, July 3-7 in Amsterdam.

7 Jul 2011

Benitec’s pain program validated by independent study

Benitec Ltd (ASX:BLT), a world leader in RNA-based gene silencing for human therapeutics, announced that China-based researchers have proved the concept behind Benitec's in house neuropathic pain program.

20 Jun 2011

Protein missing in fragile X syndrome acts as a molecular toggle switch in brain cells

New research shows how the protein missing in fragile X syndrome - the most common inherited form of intellectual disability - acts as a molecular toggle switch in brain cells.

10 Jun 2011

Scientists uncover new role for key cancer protein

Scientists at Dana-Farber Cancer Institute have uncovered a new role for a key cancer protein, a finding that could pave the way for more-effective radiation treatment of a variety of tumors.

10 Jun 2011

Microscopic worms in space

A space flight by millions of microscopic worms could help us overcome the numerous threats posed to human health by space travel. The Caenorhabditis elegans (C. elegans) have also given experts an insight into how to block muscle degradation in the sick and elderly.

2 Jun 2011